Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: neuropsychiatrie 3/2014

01.09.2014 | übersicht

Depressive und Angststörungen bei Patienten mit Epilepsie und Multipler Sklerose – eine Herausforderung für die nervenärztliche Praxis

verfasst von: Univ. Prof. Dr. Dr. Hans-Peter Kapfhammer

Erschienen in: neuropsychiatrie | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Patienten mit Epilepsie und Multipler Sklerose zeigen eine hohe Koexistenz von depressiven und Angststörungen auf. Diese Koexistenz bedeutet ein höheres subjektives Leiden, ein reduziertes Coping, mögliche negative Interferenzen mit somatischen Therapien und Rehabilitationen, eine stärkere Beeinträchtigung der Lebensqualität sowie höhere Grade an psychosozialer Behinderung. Sie schließt auch ein höheres somatisches Morbiditäts- und Mortalitätsrisiko im weiteren Verlauf ein. Die komplexen Zusammenhänge sind vorteilhaft innerhalb eines biopsychosozialen Krankheitsmodells zu integrieren. Psychologische und psychosoziale Stressoren sind eigenständig zu betrachten, aber auch in ihrer typischen neurobiologischen Vermittlung zu reflektieren. Gemeinsam geteilte pathogenetische Mechanismen von emotionaler Dysregulation einerseits und neurologischem Krankheitsprozess andererseits müssen betont werden. Vielfältige wechselseitige Interaktionen sind sowohl bei neurologischen Therapien als auch bei psychiatrischen Interventionen zu beachten.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Starkstein SE, Tranel D. Neurological and psychiatric aspects of emotion. Handb Clin Neurol. 2012;106:53–74. PubMedCrossRef Starkstein SE, Tranel D. Neurological and psychiatric aspects of emotion. Handb Clin Neurol. 2012;106:53–74. PubMedCrossRef
2.
Zurück zum Zitat Kapfhammer HP. Psychische Störungen bei somatischen Krankheiten. In: Möller HJ, Laux G, Kapfhammer HP, Herausgeber. Psychiatrie, Psychosomatik und Psychotherapie. 5. Aufl. Berlin: Springer; 2014. (in Vorbereitung). Kapfhammer HP. Psychische Störungen bei somatischen Krankheiten. In: Möller HJ, Laux G, Kapfhammer HP, Herausgeber. Psychiatrie, Psychosomatik und Psychotherapie. 5. Aufl. Berlin: Springer; 2014. (in Vorbereitung).
3.
Zurück zum Zitat Kapfhammer HP. Depressive und Angststörungen bei Patienten mit neurologischen Erkrankungen in der Perspektivität der Multimorbidität. Nervenarzt. 2014. Epub ahead of print. Kapfhammer HP. Depressive und Angststörungen bei Patienten mit neurologischen Erkrankungen in der Perspektivität der Multimorbidität. Nervenarzt. 2014. Epub ahead of print.
4.
Zurück zum Zitat Trimble MR, Schmitz B. The neuropsychiatry of epilepsy. 2nd Ed. Cambridge: Cambridge University Press; 2011. CrossRef Trimble MR, Schmitz B. The neuropsychiatry of epilepsy. 2nd Ed. Cambridge: Cambridge University Press; 2011. CrossRef
6.
Zurück zum Zitat Fuller-Thomson E, Brennenstuhl S. The association between depression and epilepsy in a nationally representative sample. Epilepsia. 2009;50:1051–8. PubMedCrossRef Fuller-Thomson E, Brennenstuhl S. The association between depression and epilepsy in a nationally representative sample. Epilepsia. 2009;50:1051–8. PubMedCrossRef
7.
Zurück zum Zitat Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007;48:2336–44. PubMed Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007;48:2336–44. PubMed
9.
Zurück zum Zitat Beyenberg S, Mitchell AJ, Schmidt D, et al. Anxiety in patients with epilepsy: systematic review and suggestions for clinical management. Epilepsy Behav. 2005;7:161–71. CrossRef Beyenberg S, Mitchell AJ, Schmidt D, et al. Anxiety in patients with epilepsy: systematic review and suggestions for clinical management. Epilepsy Behav. 2005;7:161–71. CrossRef
10.
Zurück zum Zitat Gabbs MG, Barry JJ. The link between mood disorders and epilepsy: why is it important to diagnose and treat? Adv Stud Med. 2005;5:572–8. Gabbs MG, Barry JJ. The link between mood disorders and epilepsy: why is it important to diagnose and treat? Adv Stud Med. 2005;5:572–8.
11.
Zurück zum Zitat Ettinger AB, Reed ML, Goldberg JF, Hischfeld RM. Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology. 2005;65:535–40. PubMedCrossRef Ettinger AB, Reed ML, Goldberg JF, Hischfeld RM. Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology. 2005;65:535–40. PubMedCrossRef
12.
Zurück zum Zitat Hoppe C, Elger CE. Depression in epilepsy: a critical review from a clinical perspective. Nat Rev Neurol. 2011;7:462–72. CrossRef Hoppe C, Elger CE. Depression in epilepsy: a critical review from a clinical perspective. Nat Rev Neurol. 2011;7:462–72. CrossRef
13.
Zurück zum Zitat Mula M, Jauch R, Cavanna A, et al. Interictal dysphoric disorder and periictal dysphoric symptoms in patients with epilepsy. Epilepsia. 2010;51:1139–45. PubMedCrossRef Mula M, Jauch R, Cavanna A, et al. Interictal dysphoric disorder and periictal dysphoric symptoms in patients with epilepsy. Epilepsia. 2010;51:1139–45. PubMedCrossRef
14.
Zurück zum Zitat Kanner AM, Trible M, Schmitz B. Postictal affective episodes. Epilepsy. 2010;19:156–8. Kanner AM, Trible M, Schmitz B. Postictal affective episodes. Epilepsy. 2010;19:156–8.
15.
Zurück zum Zitat Kanner AM, Hesdorffer DC. Neuropsychiatric complications of epilepsy. Handb Clin Neurol. 2012;107: 461–82. PubMedCrossRef Kanner AM, Hesdorffer DC. Neuropsychiatric complications of epilepsy. Handb Clin Neurol. 2012;107: 461–82. PubMedCrossRef
16.
Zurück zum Zitat Gaitatzis A, Sisodiya SM, Sander JW. The somatic comorbidity of epilepsy: a weight but often unrecognized burden. Epilepsia. 2012;53:1282–93. PubMedCrossRef Gaitatzis A, Sisodiya SM, Sander JW. The somatic comorbidity of epilepsy: a weight but often unrecognized burden. Epilepsia. 2012;53:1282–93. PubMedCrossRef
17.
Zurück zum Zitat Kanner AM. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? Lancet Neurol. 2012;11:1093–102. PubMedCrossRef Kanner AM. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? Lancet Neurol. 2012;11:1093–102. PubMedCrossRef
18.
Zurück zum Zitat Petrovski S, Szoeke CEI, Jones NC, et al. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology. 2010;75:1015–21. PubMedCrossRef Petrovski S, Szoeke CEI, Jones NC, et al. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology. 2010;75:1015–21. PubMedCrossRef
19.
Zurück zum Zitat Kanner AM. Depression and epilepsy: a review of multiple facets of their close relation. Neurol Clin. 2009;27:865–80. PubMedCrossRef Kanner AM. Depression and epilepsy: a review of multiple facets of their close relation. Neurol Clin. 2009;27:865–80. PubMedCrossRef
20.
Zurück zum Zitat Cleary RA, Thompson PJ, Fox Z, Foong J. Predictors of psychiatric and seizure outcome following temporal lobe epilepsy surgery. Epilepsia 2012;53:1705–12. PubMedCrossRef Cleary RA, Thompson PJ, Fox Z, Foong J. Predictors of psychiatric and seizure outcome following temporal lobe epilepsy surgery. Epilepsia 2012;53:1705–12. PubMedCrossRef
21.
Zurück zum Zitat de Ar aújo Filho GM, Gomes, Mazetto L, et al. Major depressive disorder as a predictor of a worse seizure outcome one year after surgery in patients with temporal lobe epilepsy and mesial temporal sclerosis. Seizure. 2012;21:619–23. PubMedCrossRef de Ar aújo Filho GM, Gomes, Mazetto L, et al. Major depressive disorder as a predictor of a worse seizure outcome one year after surgery in patients with temporal lobe epilepsy and mesial temporal sclerosis. Seizure. 2012;21:619–23. PubMedCrossRef
22.
Zurück zum Zitat Pompili M, Baldessarini RJ. Epilepsy: risk of suicidal behavior with antiepileptic drugs. Nat Rev Neurol. 2010;6: 651–3. PubMedCrossRef Pompili M, Baldessarini RJ. Epilepsy: risk of suicidal behavior with antiepileptic drugs. Nat Rev Neurol. 2010;6: 651–3. PubMedCrossRef
23.
Zurück zum Zitat Stefanello S, Marin-Leon L, Fernandes PT, et al. Suicidal thoughts in epilepsy: a community—based study in Brazil. Epilepsy Behav 2010;17:483–8. PubMedCrossRef Stefanello S, Marin-Leon L, Fernandes PT, et al. Suicidal thoughts in epilepsy: a community—based study in Brazil. Epilepsy Behav 2010;17:483–8. PubMedCrossRef
24.
Zurück zum Zitat Hesdorffer DC, Ishihara L, Mynepalli L, et al. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol. 2012;72:184–91. PubMedCrossRef Hesdorffer DC, Ishihara L, Mynepalli L, et al. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol. 2012;72:184–91. PubMedCrossRef
25.
Zurück zum Zitat Sander JW. Early treatment does not seem to affect the risk of mortality in epilepsy but the presence of comorbidity may. J Neurol Neurosurg Psychiatry. 2011;82:829. PubMedCrossRef Sander JW. Early treatment does not seem to affect the risk of mortality in epilepsy but the presence of comorbidity may. J Neurol Neurosurg Psychiatry. 2011;82:829. PubMedCrossRef
27.
Zurück zum Zitat Gandy M, Sharpe L, Perry KN. Psychosocial predictors of depression and anxiety in patients with epilepsy: a systematic review. J Affect Disord. 2012;140:222–32. PubMedCrossRef Gandy M, Sharpe L, Perry KN. Psychosocial predictors of depression and anxiety in patients with epilepsy: a systematic review. J Affect Disord. 2012;140:222–32. PubMedCrossRef
28.
Zurück zum Zitat Hesdorffer DC, Hauser WA, Ludvigsson P, et al. Depression and attempted suicide as risk factors for incident unprovoked seizures and epilepsy. Ann Neurol. 2006;59:35–41. PubMedCrossRef Hesdorffer DC, Hauser WA, Ludvigsson P, et al. Depression and attempted suicide as risk factors for incident unprovoked seizures and epilepsy. Ann Neurol. 2006;59:35–41. PubMedCrossRef
29.
Zurück zum Zitat Adelöw C, Andersson T, Ahlbom A, Tomson T. Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology. 2012;78:396–401. PubMedCrossRef Adelöw C, Andersson T, Ahlbom A, Tomson T. Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology. 2012;78:396–401. PubMedCrossRef
30.
Zurück zum Zitat Kanner AM. Mood disorder and epilepsy: a neurobiologic perspective of their relationship. Dialogues Clin Neurosci. 2008;10:39–45. PubMedPubMedCentral Kanner AM. Mood disorder and epilepsy: a neurobiologic perspective of their relationship. Dialogues Clin Neurosci. 2008;10:39–45. PubMedPubMedCentral
31.
Zurück zum Zitat Kanner AM. Do psychiatric comorbidities have a negative impact on the course and treatment of seizure disorders? Curr Opin Neurol. 2013;26:208–13. PubMedCrossRef Kanner AM. Do psychiatric comorbidities have a negative impact on the course and treatment of seizure disorders? Curr Opin Neurol. 2013;26:208–13. PubMedCrossRef
32.
Zurück zum Zitat Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: An analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry. 2007;15:345–54. CrossRef Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: An analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry. 2007;15:345–54. CrossRef
33.
Zurück zum Zitat Schmitz B. The effects of antiepileptics on behaviour. In: Trimble MR, Schmitz B, Editors. The neuropsychiatry of epilepsy. 2nd ed. Cambridge: Cambridge University Press; 2011. pp. 133–142. CrossRef Schmitz B. The effects of antiepileptics on behaviour. In: Trimble MR, Schmitz B, Editors. The neuropsychiatry of epilepsy. 2nd ed. Cambridge: Cambridge University Press; 2011. pp. 133–142. CrossRef
34.
Zurück zum Zitat Kanner AM. The treatment of depressive disorders in epilepsy: what all neurologists should know. Epilepsia. 2013;54:3–12. PubMedCrossRef Kanner AM. The treatment of depressive disorders in epilepsy: what all neurologists should know. Epilepsia. 2013;54:3–12. PubMedCrossRef
35.
Zurück zum Zitat Bagary M. Epilepsy, antiepileptic drugs and suicidality. Curr Opin Neurol. 2011;24:177–82. PubMedCrossRef Bagary M. Epilepsy, antiepileptic drugs and suicidality. Curr Opin Neurol. 2011;24:177–82. PubMedCrossRef
36.
Zurück zum Zitat Mula M, Sander JW. Suicide risk in people with epilepsy taking antiepileptic drugs. Bipolar Disord. 2013;15:622–7. PubMedCrossRef Mula M, Sander JW. Suicide risk in people with epilepsy taking antiepileptic drugs. Bipolar Disord. 2013;15:622–7. PubMedCrossRef
37.
Zurück zum Zitat Aldenkamp AP. Antiepileptic drugs and cognitive disorders. In: Trimble MR, Schmitz B, Editors. The neuropsychiatry of epilepsy. 2nd ed. Cambridge: Cambridge University Press; 2011. pp. 153–164. CrossRef Aldenkamp AP. Antiepileptic drugs and cognitive disorders. In: Trimble MR, Schmitz B, Editors. The neuropsychiatry of epilepsy. 2nd ed. Cambridge: Cambridge University Press; 2011. pp. 153–164. CrossRef
39.
Zurück zum Zitat Price A, Rayner L, Okon-Rocha E, et al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2011;82:914–23. PubMedCrossRef Price A, Rayner L, Okon-Rocha E, et al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2011;82:914–23. PubMedCrossRef
40.
Zurück zum Zitat Barry JJ, Ettinger AB, Friel P, et al. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav. 2008;13:1–29. CrossRef Barry JJ, Ettinger AB, Friel P, et al. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav. 2008;13:1–29. CrossRef
41.
Zurück zum Zitat Kerr MP, Mensah S, Besag F, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia. 2011;52:2133–8. PubMedCrossRef Kerr MP, Mensah S, Besag F, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia. 2011;52:2133–8. PubMedCrossRef
42.
Zurück zum Zitat Cardamone L, Salzberg MR, O’Brine TJ, Jones NC. Antidepressants therapy in epilepsy: can treating the comorbidities affect the underlying disorder? Br J Pharmacol. 2013;168:1531–54. PubMedCrossRefPubMedCentral Cardamone L, Salzberg MR, O’Brine TJ, Jones NC. Antidepressants therapy in epilepsy: can treating the comorbidities affect the underlying disorder? Br J Pharmacol. 2013;168:1531–54. PubMedCrossRefPubMedCentral
43.
Zurück zum Zitat Gilliam FG, Black KG, Carter J, et al. Depression and health outcomes in epilepsy: a randomized trial. Presented at the 61st annual meeting of the American Academy of Neurology; 2009: 25 April-02 May 2006; Seattle, Washington, USA. Gilliam FG, Black KG, Carter J, et al. Depression and health outcomes in epilepsy: a randomized trial. Presented at the 61st annual meeting of the American Academy of Neurology; 2009: 25 April-02 May 2006; Seattle, Washington, USA.
44.
Zurück zum Zitat Gandy M, Sharpe L, Perry KN. Cognitive behaviour therapy for depression in people with epilepsy: A systematic review. Epilepsia. 2013;54:1734–34. CrossRef Gandy M, Sharpe L, Perry KN. Cognitive behaviour therapy for depression in people with epilepsy: A systematic review. Epilepsia. 2013;54:1734–34. CrossRef
45.
Zurück zum Zitat Ciechanowski P, Chaytor N, Miller J, et al. PEARLS depression treatment for individuals with epilepsy: a randomized controlled trial. Epilepsy Behav. 2010;19:225–31. PubMedCrossRef Ciechanowski P, Chaytor N, Miller J, et al. PEARLS depression treatment for individuals with epilepsy: a randomized controlled trial. Epilepsy Behav. 2010;19:225–31. PubMedCrossRef
46.
Zurück zum Zitat Chaytor N, Ciechanowski P, Miller JW, et al. Long-term outcomes from the PEARLS randomized trial for the treatment of depression in patients with epilepsy. Epilepsy Behav. 2011;20:545–9. PubMedCrossRef Chaytor N, Ciechanowski P, Miller JW, et al. Long-term outcomes from the PEARLS randomized trial for the treatment of depression in patients with epilepsy. Epilepsy Behav. 2011;20:545–9. PubMedCrossRef
47.
Zurück zum Zitat Mula M. Treatment of anxiety disorders in epilepsy: An evidence-based approach. Epilepsia. 2013;54(suppl A):13–8. PubMedCrossRef Mula M. Treatment of anxiety disorders in epilepsy: An evidence-based approach. Epilepsia. 2013;54(suppl A):13–8. PubMedCrossRef
48.
Zurück zum Zitat Paparrigopoulos T, Ferentinos P, Kouzoupis A, et al. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry. 2010;22:14–21. PubMedCrossRef Paparrigopoulos T, Ferentinos P, Kouzoupis A, et al. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry. 2010;22:14–21. PubMedCrossRef
49.
Zurück zum Zitat Patten SB, Beck CA, Williams JV, Barbui C, Metz LM. Major depression in multiple sclerosis: a population-based perspective. Neurology. 2003;61:1524–27. PubMedCrossRef Patten SB, Beck CA, Williams JV, Barbui C, Metz LM. Major depression in multiple sclerosis: a population-based perspective. Neurology. 2003;61:1524–27. PubMedCrossRef
51.
Zurück zum Zitat Patten SB, Metz LM, Reimer MA. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler. 2000;6:115–20. PubMedCrossRef Patten SB, Metz LM, Reimer MA. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler. 2000;6:115–20. PubMedCrossRef
52.
Zurück zum Zitat Chwastiak L, Ehde DM, Gibbons LE, et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry. 2002;159:1862–8. PubMedCrossRef Chwastiak L, Ehde DM, Gibbons LE, et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry. 2002;159:1862–8. PubMedCrossRef
53.
Zurück zum Zitat Fisk JD, Morehouse SA, Brown MG, et al. Hospital-based psychiatric service utilization and morbidity in multiple sclerosis. Can J Neurol Sci. 1998;25:230–5. PubMed Fisk JD, Morehouse SA, Brown MG, et al. Hospital-based psychiatric service utilization and morbidity in multiple sclerosis. Can J Neurol Sci. 1998;25:230–5. PubMed
54.
Zurück zum Zitat Ghaffar O, Feinstein A. The neuropsychiatry of multiple sclerosis: a review of recent developments. Curr Opin Psychiatry. 2007;20:278–85. PubMed Ghaffar O, Feinstein A. The neuropsychiatry of multiple sclerosis: a review of recent developments. Curr Opin Psychiatry. 2007;20:278–85. PubMed
55.
Zurück zum Zitat Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler. 2007;13:67–72. PubMedCrossRef Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler. 2007;13:67–72. PubMedCrossRef
56.
Zurück zum Zitat Poder K, Ghatavi K, Fisk JD, et al. Social anxiety in a multiple sclerosis clinic population. Mult Scler. 2009;15:393–8. PubMedCrossRef Poder K, Ghatavi K, Fisk JD, et al. Social anxiety in a multiple sclerosis clinic population. Mult Scler. 2009;15:393–8. PubMedCrossRef
57.
Zurück zum Zitat Burn MN, Nawacki E, Siddique J, et al. Prospective examination of anxiety and depression before and during confirmed and pseudoexacerbations in patients with multiple sclerosis. Psychosom Med. 2013;75:76–82. CrossRef Burn MN, Nawacki E, Siddique J, et al. Prospective examination of anxiety and depression before and during confirmed and pseudoexacerbations in patients with multiple sclerosis. Psychosom Med. 2013;75:76–82. CrossRef
58.
Zurück zum Zitat Donnchadha SÓ, Burke, Bramham J, et al. Symptom overlap in anxiety and multiple sclerosis. Mult Scler. 2013;19:1349–54. CrossRef Donnchadha SÓ, Burke, Bramham J, et al. Symptom overlap in anxiety and multiple sclerosis. Mult Scler. 2013;19:1349–54. CrossRef
59.
Zurück zum Zitat Bombardier CH, Blake KD, Ehde DM, et al. Alcohol and drug abuse among persons with multiple sclerosis. Mult Scler. 2004;10:35–40. PubMedCrossRef Bombardier CH, Blake KD, Ehde DM, et al. Alcohol and drug abuse among persons with multiple sclerosis. Mult Scler. 2004;10:35–40. PubMedCrossRef
61.
Zurück zum Zitat Jongen PJ, Ter Horst AT, Brands AM. Cognitive impairment in multiple sclerosis. Minerva Med. 2012;103:73–96. PubMed Jongen PJ, Ter Horst AT, Brands AM. Cognitive impairment in multiple sclerosis. Minerva Med. 2012;103:73–96. PubMed
62.
Zurück zum Zitat Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol. 2011;7:332–42. PubMedCrossRef Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol. 2011;7:332–42. PubMedCrossRef
63.
Zurück zum Zitat Schumann R, Adamaszek M, Sommer N, Kirkby KC. Stress, depression and antidepressant treatment options in patients suffering from multiple sclerosis. Curr Pharm Des. 2012;18:5837–45. PubMedCrossRef Schumann R, Adamaszek M, Sommer N, Kirkby KC. Stress, depression and antidepressant treatment options in patients suffering from multiple sclerosis. Curr Pharm Des. 2012;18:5837–45. PubMedCrossRef
64.
Zurück zum Zitat Dahl OP, Stordal E, Lydersen, Midgard R. Anxiety and depression in multiple sclerosis. A comparative population-based study in Nord-Trøndelag County, Norway. Mult Scler. 2009;15:1495–501. PubMedCrossRef Dahl OP, Stordal E, Lydersen, Midgard R. Anxiety and depression in multiple sclerosis. A comparative population-based study in Nord-Trøndelag County, Norway. Mult Scler. 2009;15:1495–501. PubMedCrossRef
65.
Zurück zum Zitat Wood B, van der Mei IAF, Ponsonby A-L, et al. Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. Mult Scler. 2013;19:217–24. PubMedCrossRef Wood B, van der Mei IAF, Ponsonby A-L, et al. Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. Mult Scler. 2013;19:217–24. PubMedCrossRef
67.
Zurück zum Zitat Pompili M, Forte A, Palermo M, et al. Suicide risk in multiple sclerosis: a systematic review of current literature. J Psychosom Res. 2012;73:411–7. PubMedCrossRef Pompili M, Forte A, Palermo M, et al. Suicide risk in multiple sclerosis: a systematic review of current literature. J Psychosom Res. 2012;73:411–7. PubMedCrossRef
68.
Zurück zum Zitat Mohr DC, Hart SL, Julian L, et al. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 2004;328:731–5. PubMedCrossRefPubMedCentral Mohr DC, Hart SL, Julian L, et al. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 2004;328:731–5. PubMedCrossRefPubMedCentral
69.
Zurück zum Zitat Vattakatuchery JJ, Rickards H, Cavanna AE. Pathogenic mechanisms of depression in multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2011;23:261–76. PubMedCrossRef Vattakatuchery JJ, Rickards H, Cavanna AE. Pathogenic mechanisms of depression in multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2011;23:261–76. PubMedCrossRef
70.
Zurück zum Zitat Pujol J, Bello J, Deus J, et al. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology. 1997;49:1105–10. PubMedCrossRef Pujol J, Bello J, Deus J, et al. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology. 1997;49:1105–10. PubMedCrossRef
71.
Zurück zum Zitat Bakshi R, Czarnecki D, Shaikh ZA, et al. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport. 2000;11:1153–8. PubMedCrossRef Bakshi R, Czarnecki D, Shaikh ZA, et al. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport. 2000;11:1153–8. PubMedCrossRef
72.
Zurück zum Zitat Feinstein A, Roy P, Lobaugh N, et al. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology. 2004;62:586–90. PubMedCrossRef Feinstein A, Roy P, Lobaugh N, et al. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology. 2004;62:586–90. PubMedCrossRef
73.
Zurück zum Zitat Gold SM, Irwin MR. Depression and immunity: Inflammation and depressive symptoms in multiple sclerosis. Immunol Allergy Clin North Am. 2009;29:309–20. PubMedCrossRefPubMedCentral Gold SM, Irwin MR. Depression and immunity: Inflammation and depressive symptoms in multiple sclerosis. Immunol Allergy Clin North Am. 2009;29:309–20. PubMedCrossRefPubMedCentral
74.
Zurück zum Zitat Kahl KG, Kruse N, Faller H, et al. Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 2002;27:671–81. PubMedCrossRef Kahl KG, Kruse N, Faller H, et al. Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 2002;27:671–81. PubMedCrossRef
75.
Zurück zum Zitat Mohr DC, Goodkin DE, Islar J, et al. Treatment of depression is associated with suppression of nonspecific and antigen-specific TH1 responses in multiple sclerosis. Arch Neurol. 2001;58:1081–6. PubMedCrossRef Mohr DC, Goodkin DE, Islar J, et al. Treatment of depression is associated with suppression of nonspecific and antigen-specific TH1 responses in multiple sclerosis. Arch Neurol. 2001;58:1081–6. PubMedCrossRef
76.
Zurück zum Zitat Flachenecker P, Bihler I, Weber F, et al. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler. 2004;10:165–9. PubMedCrossRef Flachenecker P, Bihler I, Weber F, et al. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler. 2004;10:165–9. PubMedCrossRef
77.
Zurück zum Zitat Heesen C, Nawrath L, Reich C, et al. Fatigue in multiple sclerosis: An example for cytokine-mediated sickness behaviour. J Neurol Neurosurg Psychiatry. 2006;77:34–9. PubMedCrossRefPubMedCentral Heesen C, Nawrath L, Reich C, et al. Fatigue in multiple sclerosis: An example for cytokine-mediated sickness behaviour. J Neurol Neurosurg Psychiatry. 2006;77:34–9. PubMedCrossRefPubMedCentral
78.
Zurück zum Zitat Mohr DC, Pelletier D. A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis. Brain Behav Immun. 2006;20:27–36. PubMedCrossRef Mohr DC, Pelletier D. A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis. Brain Behav Immun. 2006;20:27–36. PubMedCrossRef
79.
Zurück zum Zitat Heesen C, Gold SM, Huitinga I, Reul JM. Stress and hypothalamic-pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis – a review. Psychoneuroendocrinology. 2007;32:604–18. PubMedCrossRef Heesen C, Gold SM, Huitinga I, Reul JM. Stress and hypothalamic-pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis – a review. Psychoneuroendocrinology. 2007;32:604–18. PubMedCrossRef
80.
Zurück zum Zitat Holsboer F, Ising M. Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol. 2010;61:81–109. PubMedCrossRef Holsboer F, Ising M. Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol. 2010;61:81–109. PubMedCrossRef
81.
Zurück zum Zitat Lublin FD, Whitaker JN, Eidelman BH, et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 1996;46:12–8. PubMedCrossRef Lublin FD, Whitaker JN, Eidelman BH, et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 1996;46:12–8. PubMedCrossRef
82.
Zurück zum Zitat Feinstein A, O’Connor P, Feinstein K. Multiple sclerosis, interferon beta-1b and depression: A prospective investigation. J Neurol. 2002;249:815–20. PubMedCrossRef Feinstein A, O’Connor P, Feinstein K. Multiple sclerosis, interferon beta-1b and depression: A prospective investigation. J Neurol. 2002;249:815–20. PubMedCrossRef
83.
Zurück zum Zitat Fragoso YD, Frota ER, Lopes JS, et al. Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis. Clin Neuropharmacol. 2010;33:312–6. PubMedCrossRef Fragoso YD, Frota ER, Lopes JS, et al. Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis. Clin Neuropharmacol. 2010;33:312–6. PubMedCrossRef
84.
Zurück zum Zitat Koch MW, Glazenborg A, Uyttenboogaart M, et al. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev. 2011;2:CD007295. doi: 10.1002/14651858.CD007295.pub2. PubMed Koch MW, Glazenborg A, Uyttenboogaart M, et al. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev. 2011;2:CD007295. doi: 10.1002/14651858.CD007295.pub2. PubMed
85.
Zurück zum Zitat Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavioral therapy, supportive-expressive group psychotherapy and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychology. 2001;69:942–9. CrossRef Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavioral therapy, supportive-expressive group psychotherapy and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychology. 2001;69:942–9. CrossRef
86.
Zurück zum Zitat Mohr DC, Likosky W, Bertagnolli A, et al. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol. 2000;68:356–61. PubMedCrossRef Mohr DC, Likosky W, Bertagnolli A, et al. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol. 2000;68:356–61. PubMedCrossRef
87.
Zurück zum Zitat Grossman P, Kappos L, Gensicke H, et al. MS quality of life, depression, and fatigue improve after mindfulness training. Neurology. 2010;75:1141–9. PubMedCrossRefPubMedCentral Grossman P, Kappos L, Gensicke H, et al. MS quality of life, depression, and fatigue improve after mindfulness training. Neurology. 2010;75:1141–9. PubMedCrossRefPubMedCentral
88.
Zurück zum Zitat Heesen C, Solari A, Giordano A, Kasper J, Köpke S. Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement. J Neurol Sci. 2011;306:192–7. PubMedCrossRef Heesen C, Solari A, Giordano A, Kasper J, Köpke S. Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement. J Neurol Sci. 2011;306:192–7. PubMedCrossRef
89.
Zurück zum Zitat Heesen C, Köpke S, Kasper J, Poettgen J, Tallner A, Mohr DC, Gold SM. Behavioral interventions in multiple sclerosis: a biopsychosocial perspective. Expert Rev Neurother. 2012;12:1089–100. PubMedCrossRef Heesen C, Köpke S, Kasper J, Poettgen J, Tallner A, Mohr DC, Gold SM. Behavioral interventions in multiple sclerosis: a biopsychosocial perspective. Expert Rev Neurother. 2012;12:1089–100. PubMedCrossRef
Metadaten
Titel
Depressive und Angststörungen bei Patienten mit Epilepsie und Multipler Sklerose – eine Herausforderung für die nervenärztliche Praxis
verfasst von
Univ. Prof. Dr. Dr. Hans-Peter Kapfhammer
Publikationsdatum
01.09.2014
Verlag
Springer Vienna
Erschienen in
neuropsychiatrie / Ausgabe 3/2014
Print ISSN: 0948-6259
Elektronische ISSN: 2194-1327
DOI
https://doi.org/10.1007/s40211-014-0105-y